检索结果 - Yu‐Waye Chu

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    Murine Models of Chronic Graft-versus-Host Disease: Insights and Unresolved Issues

    Murine Models of Chronic Graft-versus-Host Disease: Insights and Unresolved Issues 由 Yu‐Waye Chu, Ronald E. Gress

    出版 2008
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

    Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling 由 Iraj Hosseini, Kapil Gadkar, Eric Stefanich, Chi‐Chung Li, Liping Sun, Yu‐Waye Chu, Saroja Ramanujan

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function

    Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function 由 Yu‐Waye Chu, Sarfraz Memon, Susan O. Sharrow, Frances T. Hakim, Michael Eckhaus, Philip J. Lucas, Ronald E. Gress

    出版 2004
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion

    Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion 由 Yu‐Waye Chu, Sabrina Schmitz, Baishakhi Choudhury, William G. Telford, Veena Kapoor, Susan H. Garfield, David Howe, Ronald E. Gress

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution

    Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution 由 Terry J. Fry, Manoj Sinha, Matthew Milliron, Yu‐Waye Chu, Veena Kapoor, Ronald E. Gress, E. Donnall Thomas, Crystal L. Mackall

    出版 2004
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    CCL25 increases thymopoiesis after androgen withdrawal

    CCL25 increases thymopoiesis after androgen withdrawal 由 Kirsten M. Williams, Philip J. Lucas, Catherine V. Bare, Jiun Wang, Yu‐Waye Chu, Ezekiel Tayler, Veena Kapoor, Ronald E. Gress

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

    Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Mal... 由 Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu‐Waye Chu, Jae H. Park

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

    Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma 由 Binod Dhakal, Jesús G. Berdeja, Tara B. Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode Goodridge, Sarah Cooley, Bahram Valamehr, Yu‐Waye Chu, John Byon, Rafat Abonour

    出版 2022
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

    Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma 由 Veronika Bachanová, Armin Ghobadi, Krish Patel, Jae H. Park, Ian W. Flinn, Prutha Shah, Carol Wong, Cara Bickers, Péter M. Szabó, Lilly Wong, Bahram Valamehr, Siminder Atwal, Yu‐Waye Chu, Rebecca Elstrom, Paolo Strati

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

    Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer 由 Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris, Patricia LoRusso, Joo-Hee Yi, Ola M. Saad, Barbara Tong, Yu-Waye Chu, Scott N. Holden, Amita Joshi

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed... 由 Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, R. Borson, Steven Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard A. Michaelson, Sandhya Girish, Lukas C. Amler, Maoxia Zheng, Yu-Waye Chu, Barbara Klencke, Joyce O’Shaughnessy

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma 由 Ranjana H. Advani, Daniel Lebovic, Andy Chen, Mark W. Brunvand, André Goy, Elizabeth Chang, Ephraim P. Hochberg, Sreeni Yalamanchili, Robert S. Kahn, Dan Lü, Priya Agarwal, Randall C. Dere, Hsin-Ju Hsieh, Surai Jones, Yu-Waye Chu, Bruce D. Cheson

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

    An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia 由 Steven R. Leong, Siddharth Sukumaran, Maria Hristopoulos, Klára Tótpál, Shannon Stainton, Elizabeth Lu, Alfred Wong, Lucinda Tam, Robert G. Newman, Brian R. Vuillemenot, Diego Ellerman, Chen Gu, Mary Mathieu, Mark S. Dennis, Allen Nguyen, Bing Zheng, Crystal Zhang, Genee Lee, Yu‐Waye Chu, Rodney A. Prell, Kedan Lin, Steven T. Laing, Andrew G. Polson

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

    Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results... 由 Lihua E. Budde, Laurie H. Sehn, Sarit Assouline, Ian W. Flinn, Iris Isufi, Sung‐Soo Yoon, Won-Seog Kim, Matthew J. Matasar, Loretta J. Nastoupil, Raoul Santiago, Youngil Koh, Genevive Hernandez, Chi‐Chung Li, Priya R Kulkarni, Bruce McCall, Scott McClellan, Shen Yin, Vinita Gupta, Yu‐Waye Chu, Nancy L. Bartlett

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) 由 Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani, Laurie H. Sehn, Catherine Diefenbach, Kathryn S. Kolibaba, Oliver W. Press, Gilles Salles, Hervé Tilly, Andy I. Chen, Sarit Assouline, Bruce D. Cheson, Martin Dreyling, Anton Hagenbeek, Pier Luigi Zinzani, Surai Jones, Ji Cheng, Dan Lü, Elicia Penuel, Jamie Hirata, Michael Wenger, Yu-Waye Chu, Jeff P. Sharman

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

    DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma 由 Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu, Randall C. Dere, MaryAnn Go, Jeffrey Lau, Bing Zheng, Kristi Elkins, Dimitry M. Danilenko, Katherine R. Kozak, Pamela Chan, Josefa Chuh, Xiaoyan Shi, Denise Nazzal, Franklin Fuh, Jacqueline McBride, Vanitha Ramakrishnan, Ruth de Tute, Andy C. Rawstron, Andrew Jack, Rong Deng, Yu‐Waye Chu, David Dornan, Marna Williams, William Ho, Allen Ebens, Saileta Prabhu, Andrew G. Polson

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: